Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg Breastfeeding
Breast milk is superior in nutrition, It provides resistance against infections and allergies, It is naturally sterile. Despite all the advantages of breastfeeding some mothers choose to pause the breastfeeding in fear of harmful effects of medicines passing in breast milk. Are you wondering about breastfeeding and using Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg ? Know what is Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg and how it can affect your breast milk and whether Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg is safe for your kid or not.

What is Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg ?


Olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ]. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevatedsystolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Olmesartan medoxomil and hydrochlorothiazide tablets may be used alone, or in combination with other antihypertensive drugs. Olmesartan medoxomil and hydrochlorothiazide tablets are a combination of olmesartan, an angiotensin II receptor blocker and hydrochlorothiazide, a thiazide diuretic indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1)

Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg safe in breastfeeding?

Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg low risk for breastfeeding
Olmesartan medoxomil and Hydrochlorothiazide are the two main ingredients of Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg. Based on our individual analysis of Olmesartan medoxomil and Hydrochlorothiazide we can safely say that Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg has low risk while breastfeeding. Below we have summarized the usage of Olmesartan medoxomil and Hydrochlorothiazide while breastfeeding, we recommend you to go through it for better understanding of your usage.

Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers It is not known whether olmesartan is excreted in human milk, but olmesartan is secreted at low concentration in the milk of lactating rats. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue olmesartan medoxomil and hydrochlorothiazide, taking into account the importance of the drug to the mother.

Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg Breastfeeding Analsys


Olmesartan medoxomil while Breastfeeding

Low Risk

CAS Number: 144689-63-4

At latest update, relevant published data on excretion into breast milk were not found. A high protein-binding capacity makes excretion into breast milk unlikely. In addition, a low oral bioavailability makes difficult the absorption towards the infant's plasma from ingested milk, except in prematures or newborns who may show an increased absorption. Case report of kidney function impairment of a baby whose mother had taken Telmisartan in pregnancy. Until more data on this medication is available, safer alternative drugs are preferred, especially in premature babies or during the neonatal period. Should an ARA-II medication (Sartan type) be necessary, the associated risk may be decreased by choosing the one with a favorable pharmacokinetics (shorter half-life elimination time and lower bioavailability) like Eprosartan and Losartan

Hydrochlorothiazide while Breastfeeding

Safe

CAS Number: 58-93-5

Thiazide diuretic drug. Excretion into breast milk is clinically non-significant. No side-effects were observed in a one-month old breastfed baby whose mother was treated with this medication. Drug level in the plasma of this child was undetectable. Long-term treatment with diuretic drugs (particularly Thiazide type ones with long-lasting effect and loop-acting mechanism) may inhibit lactation, mostly if lactation is not well-established yet. Use as lower dose as possible, especially during the first postnatal month. American Academy of Pediatrics 2013: Maternal Medication Usually Compatible With Breastfeeding. WHO Model List of Essential Drugs 2002: Compatible with breastfeeding.


Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg Breastfeeding Analsys - 2


Hydrochlorothiazide while Breastfeeding

CAS Number: 58-93-5

Hydrochlorothiazide doses of 50 mg daily or less are acceptable during lactation. Intense diuresis with large doses may decrease breastmilk production.



What if I already have used Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg?

Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg is in the category of low risk, if you have already used it then its not a big deal if health and behavior of baby is good. However your health care provider shall be aware of the fact that you have used Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg so you should inform him based on your convenience.


My doctor has prescribed me Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg, what should I do?

Though Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg dose not comes in category of safe drugs rather it comes in category of low risk but if your doctor is aware that you are breastfeeding your baby and has still recommended it then its advantages must be outweighing the risks.


If I am using Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg, will my baby need extra monitoring?

Not much monitoring required while using Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg


Who can I talk to if I have questions about usage of Olmesartan Medoxomil And Hydrochlorothiazide Olmesartan Medoxomil 50 Mg, Hydrochlorothiazide 50 Mg in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week